Ready for the Talk
"Diet, exercise, oral medications, and I’m still not controlled."
- Ready for the Talk

Timely insulinization may be needed for achievement of A1C goal.1

You may want to have the insulin talk sooner

Insulin may help improve a patient's glycemic control.

Rethinkinsulin.com Rethinkinsulin.com Rethinkinsulin.com A1C Parameters for ADA and AACE

For patients with suboptimal glycemic control, despite OADs and lifestyle modifications, adding insulin, as part of an overall antidiabetes regimen, may be a viable solution to help them reach their A1C goal.1

  • Timely insulinization may be needed for achievement of A1C goal1
  • In 2005, about 27% of patients with diabetes in the U.S. were on some type of insulin treatment2

Who may be an appropriate candidate for insulin?

  • A1C not at goal despite optimized oral medications
  • Patient is dieting and exercising
  • Fasting glucose is consistently above goal
  • Willingness to monitor blood glucose daily
Next >

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Please click here for full prescribing information

a A1C is the primary target for glycemic control. Goals should be individualized.
b Referenced to a nondiabetic range of 4.0% to 6.0% using a DCCT-based assay.
c Measurement should be taken 1 to 2 hours after the beginning of a meal.


References: 1. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocr Pract. 2007;13
(suppl 1):4-68.
2. CDC. National diabetes fact sheet; United States, 2005.
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005. Accessed October 2009.